Hematology (Blood Disorders)

Montefiore Einstein Hematology (Blood Disorders) is one of the largest programs of its kind in the country, and is a globally recognized leader, providing comprehensive, state-of-the-art care for adults and children with the full range of inherited and acquired nonmalignant hematologic conditions, from anemias and hemoglobinopathies to bleeding disorders and thrombosis.

Our multidisciplinary team of world-renowned hematologists collaborates closely with hematopathologists, geneticists, endocrinologists, nephrologists, rheumatologists, immunologists, obstetricians, gynecologists, oncologists, surgeons, primary care providers and other specialists to provide seamless and coordinated compassionate care.

We are proud members of the National Alliance of Sickle Cell Centers, the American Thrombosis & Hemostasis Network and the American Society of Hematology, reflecting our commitment to advancing research, improving outcomes and delivering the highest standards of care in hematology. Our programs are also accredited by the Foundation for the Accreditation of Cellular Therapy, recognizing excellence in cellular therapy and transplantation services.

A Legacy of Firsts in Hematology Innovation

We were among the first in the nation to manage bridging anticoagulation as an outpatient therapy for thrombosis. As pioneers in hematopoietic stem cell research and transplantation methods, our paradigm-shifting discoveries have led to the development of many of the latest treatments used today, including transformative therapies for vaso-occlusion in sickle cell disease (SCD). We use the most up-to-date Food and Drug Administration (FDA)-approved and newly emerging therapies to effectively manage symptoms, prevent complications, achieve remission or a cure, and improve the quality of life for each patient. 

Home to the first sickle cell center and research laboratory in the U.S., we have been at the forefront of innovation in research, education and advancing clinical care for blood disorders for more than 70 years. 

Expert Care Across the Full Spectrum of Blood Disorders

We are one of the few gene-therapy-certified treatment centers for SCD in the U.S. and one of the nation’s premier destinations for clotting disorders. Our Thrombosis Prevention and Treatment Program and Sickle Cell Center are among the largest programs of their kind in the nation, and our Health Resources and Services Administration-designated Comprehensive Adult Hemostasis & Thrombosis Center is the first to be approved in the New England region for more than 40 years. 

Our specialists use an integrated and personalized care approach tailored to each patient. We offer state-of-the-art laboratory and hematopathologic testing, including next-generation genomic sequencing, we work hand in hand with interventional surgical teams for periprocedural planning and we help diagnose malignant blood conditions.

We offer the latest hematologic, morphologic, genetic and genomic testing, including next-generation sequencing, to help inform optimal management and prognosis and facilitate precision care plans. We use advanced bone marrow aspiration and biopsy techniques and incorporate digital morphology and artificial-intelligence-driven assessments to enhance the accuracy and efficiency of identifying pathologic bone marrow and blood cells. Our in-house American Society for Histocompatibility and Immunogenetics-accredited immunology laboratory offers state-of-the-art histocompatibility, immunology and immunogenetics testing, including the latest human leukocyte antigen typing, antibody and cross-match testing techniques to ensure the best possible outcomes for patients.

For prenatal diagnosis, we also offer advanced noninvasive prenatal screening tests and work together with specialists from our Department of Obstetrics & Gynecology and Women's Health who specialize in performing chorionic villus sampling, amniocentesis and cordocentesis to collect circulating fetal cells, as well as sophisticated blastocyst biopsy for pre-implantation embryo diagnostics.

We closely monitor our patients to prevent, detect and treat blood clots, bleeding issues or malignant transformations. When needed, we use advanced imaging like venous duplex ultrasonography, ventilation/perfusion scans, computed tomography (CT) pulmonary angiography, high-resolution 3T magnetic resonance imaging, CT and positron emission tomography scans.

Our world-renowned team leads groundbreaking research in blood disorders, partnering with major organizations like the Centers for Disease Control and Prevention, National Institutes of Health (NIH), American Society of Hematology (ASH) and American Thrombosis and Hemostasis Network (ATHN) to develop new diagnostics and treatments. Through clinical trials, we help set new standards of care and have contributed to FDA approvals of innovative medications. These trials also give patients access to emerging therapies that are not yet available to the public.

Our research spans from understanding blood disorder biology and genetics to improving treatment options like stem cell therapy and immune modulation. We contribute to national studies through organizations such as NIH, ASH and ATHN, which help improve patient care. Our work has advanced knowledge in areas like anticoagulation guidelines for COVID-19 and the diagnosis and treatment of Evans syndrome.

We have played a key role in SCD research, exploring genetic factors, treatment approaches like gene therapy, and new care strategies. By collaborating with data experts, we use machine learning to enhance patient care and standardize pain management protocols. Our contributions continue to shaping the future of hematology and improving patient outcomes.